Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAUVID vs LYMPHOSEEK KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
PET imaging of tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease
For lymphoscintigraphy to assist in the localization of sentinel lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
18 mg intravenously once daily.
Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals; may be prolonged in patients with renal impairment.
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Not metabolized; eliminated primarily by renal excretion as intact drug
Technetium Tc-99m tilmanocept is not metabolized; it is cleared from the injection site via the lymphatic system and excreted renally.
Primarily renal excretion as unchanged drug (approximately 70%) with biliary/fecal elimination accounting for about 20-30%.
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Approximately 85-90% bound to serum albumin and alpha-1-acid glycoprotein.
Negligible (<5%), primarily to albumin.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Approximately 0.2 L/kg, indicating distribution within extracellular fluid.
Subcutaneous bioavailability is approximately 60-70% relative to intravenous administration.
Not applicable (administered parenterally).
No dose adjustment required for any degree of renal impairment.
No dose adjustment required based on GFR, but ensure adequate hydration.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific guidelines available; use with caution in severe hepatic impairment.
Not approved for pediatric use; safety and efficacy not established.
Not established; safety and efficacy in pediatric patients have not been studied.
No specific dose adjustment recommended; use standard adult dosing.
No specific dosage adjustment; monitor for adverse effects as elderly may have reduced immune response.
None
This drug does not have a black box warning.
Image interpretation errors due to presence of non-specific binding or off-target uptake,Risk of misdiagnosis if used as a sole diagnostic tool,Radiation exposure risk; drug is radioactive
Risk of hypersensitivity reactions including anaphylaxis.,Not for intrathecal administration.,Radiation exposure risk.
Known hypersensitivity to flortaucipir or any excipient
Known hypersensitivity to tilmanocept or any component of the formulation.
No specific food interactions. Patients should avoid caffeine and alcohol for 24 hours prior to the scan as they may affect brain activity, though not specifically contraindicated. Maintain normal diet but avoid heavy meals immediately before the procedure.
No known food interactions. No dietary restrictions required.
FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequate human studies exist. First trimester: theoretical risk of fetal radiation exposure (estimated fetal absorbed dose <1 m Gy from a single administration), considered minimal. Second/third trimester: radiation risk similar; no known teratogenic effects. Overall, risk is low but exposure should be avoided unless benefit clearly outweighs risk.
Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended doses. However, if administered intravenously, radiation exposure to the fetus could occur. No teratogenic effects are expected from the non-radioactive component (tilmanocept). Pregnancy category not assigned by FDA for diagnostic radiopharmaceuticals. Use only if clearly needed.
No data on excretion into human milk. M/P ratio unknown. Due to short physical half-life (110 minutes) and low administered activity, breastfeeding interruption of 4 hours (10 half-lives) is recommended to minimize infant radiation exposure. Alternatively, pump and discard for 4 hours post-injection.
It is unknown whether tilmanocept is excreted in human milk. Because of the low dose and local administration, systemic exposure is minimal. However, to minimize radiation exposure to the nursing infant, temporary cessation of breastfeeding for 4-6 hours after administration is recommended. M/P ratio not available.
No dosing adjustment needed. The administered activity (370 MBq ±10%) is fixed; no pharmacokinetic changes in pregnancy necessitate dose alteration.
No dose adjustment necessary. The administered activity of technetium Tc 99m tilmanocept is typically 18.5-74 MBq (0.5-2.0 m Ci) regardless of pregnancy. Pharmacokinetic changes in pregnancy are not expected to require dose modification due to local subcutaneous administration.
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent indicated for PET imaging of tau pathology in patients with cognitive impairment being evaluated for Alzheimer's disease. Administer intravenously as a bolus injection (10 m Ci, 370 MBq). Image acquisition should begin approximately 80 minutes post-injection. False positives may occur in patients with prior strokes, brain tumors, or other causes of tau deposition. Do not use for screening or early-stage disease without cognitive symptoms. Ensure patient is well hydrated before administration. The effective radiation dose is about 7 m Sv.
Lymphoseek (technetium Tc 99m tilmanocept) is a receptor-targeted radiotracer for sentinel lymph node mapping. Administer intradermally, subcutaneously, or peritumorally. Optimal imaging time: 15-60 min post-injection. Can be used in patients with penicillin allergy as it contains no penicillin. Ensure patient is not pregnant or lactating. May cause injection site reactions.
TAUVID is a radioactive tracer used to detect tau protein tangles in the brain, which are associated with Alzheimer's disease.,You will receive a single injection into a vein. The scan will start about 80 minutes after the injection and lasts approximately 30 minutes.,Drink plenty of water before the procedure to help eliminate the radioactive material from your body.,You may experience mild discomfort at the injection site, but serious side effects are rare.,The amount of radiation exposure is low and similar to other diagnostic imaging procedures, but inform your doctor if you are pregnant or breastfeeding.,Results do not provide a definitive diagnosis but help your doctor evaluate your condition.
This is a radioactive dye used to find lymph nodes during surgery.,You will receive a small injection near the tumor site.,The procedure is generally safe, but inform your doctor if you are pregnant or breastfeeding.,You may experience mild pain, redness, or swelling at the injection site.,No special dietary restrictions are needed before the procedure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAUVID vs LYMPHOSEEK KIT, answered by our medical review team.
TAUVID is a Radiopharmaceutical Diagnostic Agent that works by TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.. LYMPHOSEEK KIT is a Radiopharmaceutical Diagnostic Agent that works by Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAUVID and LYMPHOSEEK KIT depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAUVID is: 18 mg intravenously once daily.. The standard adult dose of LYMPHOSEEK KIT is: Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAUVID and LYMPHOSEEK KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAUVID is classified as Category C. FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequ. LYMPHOSEEK KIT is classified as Category C. Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.